Source comparison
BPC-157 for Marathon Recovery Research: Safety, Efficacy, Recovery Comparison
Mechanism VEGF upregulation, FAK-paxillin modulation, angiogenesis promotion COX enzyme inhibition, inflammation suppression Time-dependent collagen remodeling BPC-157 targets repair pathways NSAIDs don't. Mechanistically complementary, not redundant Tendon He
This comparison does not assign a generated winner or score.
- Mechanism
- VEGF upregulation, FAK-paxillin modulation, angiogenesis promotion
- COX enzyme inhibition, inflammation suppression
- Time-dependent collagen remodeling
- BPC-157 targets repair pathways NSAIDs don't. Mechanistically complementary, not redundant
- Tendon Healing Timeline
- 30–50% reduction in animal models (4-week vs 6-week return to baseline strength)
- No acceleration. Masks pain only
- 6–12 weeks standard
- Rodent data shows clear advantage; human extrapolation requires clinical trials
- Gastric Side Effects
- Protective. Reduces exercise-induced gut permeability
- Ulcerogenic. Damages gastric mucosa through COX-1 inhibition
- None
- BPC-157 may counteract NSAID damage, though no direct human trials exist
- Regulatory Status
- Research-only. Not FDA-approved for human use
- FDA-approved, widely available
- N/A
- Legal for research purposes through licensed peptide suppliers only
- Cost (28-day supply)
- $80–$150 for research-grade peptide
- $10–$30 OTC
- $0
- BPC-157 cost justified only in research context; anecdotal use lacks clinical oversight
- Evidence Quality
- Animal models, observational case reports
- Decades of clinical trial data
- BPC-157 shows promise but lacks Phase III human trials. Efficacy claims remain speculative